|
?:authorAffiliation
|
-
[\'School of Cancer & Pharmaceutical Sciences, King\'s College London, London, UK.\', \'Institute of Biomedical Engineering, University of Oxford, Oxford, UK.\', \'School of Cancer & Pharmaceutical Sciences, King\'s College London, London, UK; Breast Cancer Now Research Unit, King\'s College London, London, UK.\', \'Cancer Immunotherapy Accelerator, UCL Cancer Institute, University College and King\'s College, London, UK; Peter Gorer Department of Immunobiology, King\'s College London, London, UK.\', \'Peter Gorer Department of Immunobiology, King\'s College London, London, UK.\', \'The Francis Crick Institute, London, UK.\', \'Oncology and Haematology Clinical Trials (OHCT), Guy\'s and St Thomas\' NHS Foundation Trust, London UK.\', \'Wolfson Centre for Age-Related Diseases, IoPPN, King\'s College London, London, UK.\', \'Department of Inflammation Biology, King\'s College London, London, UK.\', \'Peter Gorer Department of Immunobiology, King\'s College London, London, UK; Department of Intensive Care Medicine, Guy\'s and St Thomas\' NHS Foundation Trust, London, UK.\', \'Department of Infectious Diseases, King\'s College London, London, UK.\', \'Department of Haematology, Guy\'s and St Thomas\' NHS Foundation trust, London, UK.\', \'Department of Medical Oncology Guy\'s and St Thomas\' NHS Foundation Trust, London, UK.\', \'Department of Translational Oncology & Urology Research (TOUR), King\'s College London, London, UK.\', \'Targeted Therapy Team, The Institute of Cancer Research, London, UK.\', \'London Institute for Mathematical Sciences, Mayfair, London, UK; Saddle Point Science Ltd, London, UK.\', \'School of Cancer & Pharmaceutical Sciences, King\'s College London, London, UK; Department of Haematological Medicine, King\'s College Hospital, London, UK.\', \'School of Cancer & Pharmaceutical Sciences, King\'s College London, London, UK; Cancer Immunotherapy Accelerator, UCL Cancer Institute, University College and King\'s College, London, UK; Peter Gorer Department of Immunobiology, King\'s College London, London, UK; The Francis Crick Institute, London, UK.\', \'Systems Immunity University Research Institute and Division of Infection and Immunity, Cardiff University, Cardiff, UK.\', \'Department of Gastroenterology, Princess Royal University Hospital, Kent, UK.\', \'Department of Haematological Medicine, King\'s College Hospital, London, UK.\', \'School of Cancer & Pharmaceutical Sciences, King\'s College London, London, UK; Department of Haematology, Guy\'s and St Thomas\' NHS Foundation trust, London, UK.\', \'Breast Cancer Now Research Unit, King\'s College London, London, UK; St. John\'s Institute of Dermatology, King\'s College London, London, UK; NIHR Biomedical Research Centre, and King\'s College London, London, UK.\', \'Targeted Therapy Team, The Institute of Cancer Research, London, UK; London Institute for Mathematical Sciences, Mayfair, London, UK; Saddle Point Science Ltd, London, UK; Department of Biophysics, Radboud University, Nijmegen, The Netherlands.\', \'School of Cancer & Pharmaceutical Sciences, King\'s College London, London, UK; Department of Medical Oncology Guy\'s and St Thomas\' NHS Foundation Trust, London, UK.\', \'Peter Gorer Department of Immunobiology, King\'s College London, London, UK; The Francis Crick Institute, London, UK.\', \'School of Cancer & Pharmaceutical Sciences, King\'s College London, London, UK; Department of Haematological Medicine, King\'s College Hospital, London, UK; Medical Research Council (MRC) Clinical Academic Research Partnership, London, UK.\', \'School of Cancer & Pharmaceutical Sciences, King\'s College London, London, UK; Breast Cancer Now Research Unit, King\'s College London, London, UK; Department of Medical Oncology Guy\'s and St Thomas\' NHS Foundation Trust, London, UK; Cancer Research UK (CRUK) Clinician Scientist, London, UK. Electronic address: sheeba.irshad@kcl.ac.uk.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}